Analysis of the incentive effect of the patent linkage system on the application of generic drugs in China and suggestions for countermeasures

CAO Jiacheng; FAN Jiaxun; WANG Wenzhu

doi:10.6039/j.issn.1001-0408.2023.19.02

您当前的位置：

首页 >

文章列表页 >

Analysis of the incentive effect of the patent linkage system on the application of generic drugs in China and suggestions for countermeasures

更新时间：2025-09-26

- Analysis of the incentive effect of the patent linkage system on the application of generic drugs in China and suggestions for countermeasures
- ZHONGGUO YAOFANG Vol. 34, Issue 19, Pages: 2311-2315(2023)
- 作者机构：
  
  江苏省药品监督管理局审核查验中心，南京　210019
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.19.02
  CLC： R95
- Received：03 April 2023，
  
  Revised：2023-08-30，
  
  Accepted：30 August 2023，
  
  Published：15 October 2023
- 稿件说明：
移动端阅览
曹嘉成,樊嘉训,王闻珠.专利链接制度对我国仿制药申报的激励效果分析及对策建议[J].中国药房,2023,34(19):2311-2315.

CAO Jiacheng,FAN Jiaxun,WANG Wenzhu.Analysis of the incentive effect of the patent linkage system on the application of generic drugs in China and suggestions for countermeasures[J].ZHONGGUO YAOFANG,2023,34(19):2311-2315.
曹嘉成,樊嘉训,王闻珠.专利链接制度对我国仿制药申报的激励效果分析及对策建议[J].中国药房,2023,34(19):2311-2315. DOI： 10.6039/j.issn.1001-0408.2023.19.02.

CAO Jiacheng,FAN Jiaxun,WANG Wenzhu.Analysis of the incentive effect of the patent linkage system on the application of generic drugs in China and suggestions for countermeasures[J].ZHONGGUO YAOFANG,2023,34(19):2311-2315. DOI： 10.6039/j.issn.1001-0408.2023.19.02.

摘要

目的

为优化专利链接制度体系，鼓励仿制药申报上市提供参考。

方法

在文献研究的基础上，结合笔者工作经验比较分析专利链接制度在我国实行后仿制药申报及专利挑战的情况，根据专利链接制度对我国仿制药专利挑战激励不足的原因进行分析，并提出相应的对策建议。结果与

结论

我国专利链接制度于2021年落地，但由于制度施行仍在起步阶段，实践指导的相关文件尚不完善，配套的激励机制尚不健全，导致仿制药企业发起专利挑战的意愿不强。建议我国可以从丰富仿制药信息登记平台功能、培育专业的药品专利代理机构、建立首仿药共同挑战平台等方面，进一步完善专利链接配套制度，进而激励我国仿制药企业提高创新动力，挑战原研药专利并申报上市，通过充分竞争达到平抑药价、造福百姓的效果。

Abstract

OBJECTIVE

To optimize the system of patent linkage system and provide a reference for encouraging generic drugs to apply for listing.

METHODS

On the basis of literature research， combined with the author’s work experience， the situation of generic drug application and patent challenge were analyzed comparatively after the implementation of the patent linkage system in China. Based on the patent linkage system， the reasons for the insufficient incentive for the challenge of generic drug patents in China were analyzed； corresponding countermeasures and suggestions were proposed.

RESULTS &

CONCLUSIONS

The patent linkage system in China was implemented in 2021， but due to the implementation of the system being still in its initial stage， the relevant documents for practical guidance are not yet complete， and the supporting incentive mechanism is not yet sound， resulting in a weak willingness of generic pharmaceutical enterprises to initiate patent challenges. It is suggested that China can further improve the patent linkage system by improving the patent information registration platform of generic drugs， developing professional drug patent agencies， and establishing the patent common challenges platform of the first generic drug， in order to incentivize Chinese generic drug enterprises to increase innovation motivation， challenge original research drug patents， and apply for listing， achieving the effect of suppressing drug prices and benefiting the people through full competition.

关键词

Keywords

references

耿立冬，刘南岑 . 药品专利链接制度溯源 [J ] . 中国科技信息， 2021 （ 23 ）： 21 - 24 .

GENG L D ， LIU N C . Traceability of pharmaceutical patent linkage system [J ] . China Sci Technol Inf ， 2021 （ 23 ）： 21 - 24 .

韩镭，刘桂明 . 浅析药品专利链接制度带来的机遇和挑战 [J ] . 中国发明与专利， 2019 ， 16 （ 3 ）： 17 - 23 .

HAN L ， LIU G M . Opportunity and challenge from pharmaceutical patent linkage system [J ] . China Invent Pat ， 2019 ， 16 （ 3 ）： 17 - 23 .

王圣鸣，田侃，王紫红 . 我国鼓励仿制药品目录政策趋势研究 [J ] . 中国药房， 2021 ， 32 （ 17 ）： 2053 - 2058 .

WANG S M ， TIAN K ， WANG Z H . Study on the policy trends of encouraged generic drug catalogue in China [J ] . China Pharm ， 2021 ， 32 （ 17 ）： 2053 - 2058 .

孙旭丽，马韶青 . 我国鼓励仿制药品优先审评制度的现状及完善对策 [J ] . 中国药房， 2023 ， 34 （ 2 ）： 129 - 132 .

SUN X L ， MA S Q . Status quo and improvement countermeasures of the priority review system for encouraged generic drug in China [J ] . China Pharm ， 2023 ， 34 （ 2 ）： 129 - 132 .

中国医药创新促进会 . 国内首个专利挑战成功的仿制药帕罗西汀胶囊获得美国A号 [EB/OL ] .[ 2023-08-22 ] . http：//www.phirda.com/artilce_13982.html http://www.phirda.com/artilce_13982.html .

China Pharmaceutical Innovation Promotion Association . China first successful patent challenge for paroxetine capsules approved ANDA by FDA [EB/OL ] .[ 2023-08-22 ] . http：//www.phirda.com/artilce_13982.html http://www.phirda.com/artilce_13982.html .

GRABOWSKI H . Pharmaceutical patent challenges and their implications for innovation and generic competition [EB/OL ] .[ 2023-08-22 ] . https：//ashecon.confex.com/ashecon/2014/webprogram/Paper2517.html https://ashecon.confex.com/ashecon/2014/webprogram/Paper2517.html .

管荣齐，刘少华 . 药品专利挑战的机制和策略 [J ] . 沈阳工业大学学报（社会科学版）， 2022 ， 15 （ 2 ）： 97 - 103 .

GUAN R Q ， LIU S H . Mechanism and strategy of drug patent challenge [J ] . J Shenyang Univ Technol Soc Sci ， 2022 ， 15 （ 2 ）： 97 - 103 .

崔秀娟，李明阳，梅之清，等 . 集采常态化背景下重构我国仿制药新格局：基于印度的5点启示 [J ] . 卫生软科学， 2022 ， 36 （ 10 ）： 65 - 68 .

CUI X J ， LI M Y ， MEI Z Q ， et al . Reconstruction of a new pattern of generic drugs in China under the background of normal intensive collection：based on 5 lessons from India [J ] . Soft Sci Health ， 2022 ， 36 （ 10 ）： 65 - 68 .

上海阳光医药采购网 . 4+7城市药品集中采购拟中选结果公示 [EB/OL ] .[ 2023-08-22 ] . https：//www.smpaa.cn/gjsdcg/2018/12/07/8531.shtml https://www.smpaa.cn/gjsdcg/2018/12/07/8531.shtml .

Sunshine Medical Procurement All-In-One . Announcement of proposed winning results for 4+7 urban drug centralized procurement [EB/OL ] .[ 2023-08-22 ] . https：//www.smpaa.cn/gjsdcg/2018/12/07/8531.shtml https://www.smpaa.cn/gjsdcg/2018/12/07/8531.shtml .

陈珉惺，吴卿仪，徐源，等 . 国家药品集中带量采购常态化下接续探索与启示 [J ] . 中国医疗保险， 2022 （ 8 ）： 61 - 66 .

CHEN M X ， WU Q Y ， XU Y ， et al . Exploration and enlightenment of normalization of national centralized drug procurement follow-up [J ] . China Health Insur ， 2022 （ 8 ）： 61 - 66 .

谢顺星 . 我国专利代理事业近十年的发展与展望 [J ] . 专利代理， 2022 （ 3 ）： 14 - 18 .

XIE S X . The development and prospects of patent agency in China in the last decade [J ] . Pat Agency ， 2022 （ 3 ）： 14 - 18 .

王媛，邵蓉，颜建周 . 对标国际规则的我国药品专利链接制度实施策略探索 [J ] . 中国药房， 2022 ， 33 （ 21 ）： 2566 - 2571 .

WANG Y ， SHAO R ， YAN J Z . Exploration on the implementation strategy of China’s drug patent link system based on benchmarking international rules [J ] . China Pharm ， 2022 ， 33 （ 21 ）： 2566 - 2571 .

赵飞，赵紫楠，薛薇，等 . 我国国家基本药物目录中仿制药参比制剂设立情况研究 [J ] . 中国药事， 2021 ， 35 （ 9 ）： 1000 - 1006 .

ZHAO F ， ZHAO Z N ， XUE W ， et al . On the establishment of generic reference formulations in China’s national essential drug list [J ] . Chin Pharm Aff ， 2021 ， 35 （ 9 ）： 1000 - 1006 .

朱春奎，毛万磊 . 议事协调机构、部际联席会议和部门协议：中国政府部门横向协调机制研究 [J ] . 行政论坛， 2015 ， 22 （ 6 ）： 39 - 44 .

ZHU C K ， MAO W L . Research on the horizontal coordination mechanism of Chinese government departments .[J ] . Adm Tribune ， 2015 ， 22 （ 6 ）： 39 - 44 .

Views

468

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment of Drug Registration Applicant Compliance Management Organizations in the United States and Its Enlightenment to China

Related Author

YAO Yi

ZHAO Yanjiao

FAN Xin

CHEN Yongfa

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰